199 related articles for article (PubMed ID: 25361806)
21. [Molecular biology and treatment of CML].
Kimura S
Rinsho Ketsueki; 2017; 58(10):1920-1930. PubMed ID: 28978834
[TBL] [Abstract][Full Text] [Related]
22. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
23. Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia.
Bar M; Radich J
J Natl Compr Canc Netw; 2013 Mar; 11(3):308-15. PubMed ID: 23486457
[TBL] [Abstract][Full Text] [Related]
24. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cortes JE; Kantarjian HM; Rea D; Wetzler M; Lipton JH; Akard L; Khoury HJ; Michallet M; Guerci-Bresler A; Chuah C; Hellmann A; Digumarti R; Parikh PM; Legros L; Warzocha K; Baccarani M; Li E; Munteanu M; Nicolini FE
Cancer; 2015 May; 121(10):1637-44. PubMed ID: 25586015
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib.
Nicolini FE; Alcazer V; Cony-Makhoul P; Heiblig M; Morisset S; Fossard G; Bidet A; Schmitt A; Sobh M; Hayette S; Mahon FX; Dulucq S; Etienne G
Exp Hematol; 2018 Aug; 64():97-105.e4. PubMed ID: 29800673
[TBL] [Abstract][Full Text] [Related]
26. Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.
Mukherjee S; Kalaycio M
Curr Hematol Malig Rep; 2016 Apr; 11(2):86-93. PubMed ID: 26932346
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.
Fernandez HF; Kharfan-Dabaja MA
Cancer Control; 2009 Apr; 16(2):153-7. PubMed ID: 19337201
[TBL] [Abstract][Full Text] [Related]
28. Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
Ruggiu M; Oberkampf F; Ghez D; Cony-Makhoul P; Beckeriche F; Cano I; Taksin AL; Benbrahim O; Ghez S; Farhat H; Rigaudeau S; de Gunzburg N; Lara D; Terre C; Raggueneau V; Garcia I; Spentchian M; De Botton S; Rousselot P
Leuk Lymphoma; 2018 Jul; 59(7):1659-1665. PubMed ID: 29179634
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Lee SE; Choi SY; Kim SH; Jang EJ; Bang JH; Byeun JY; Park JE; Jeon HR; Oh YJ; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Lee JW; Min WS; Park CW; Kim DW
Hematology; 2014 Mar; 19(2):63-72. PubMed ID: 23684143
[TBL] [Abstract][Full Text] [Related]
30. When to Consider Allogeneic Transplantation in CML.
Radich J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S93-5. PubMed ID: 27521333
[TBL] [Abstract][Full Text] [Related]
31. Development of an effective therapy for chronic myelogenous leukemia.
Woessner DW; Lim CS; Deininger MW
Cancer J; 2011; 17(6):477-86. PubMed ID: 22157291
[TBL] [Abstract][Full Text] [Related]
32. [Management of advanced-phase chronic myeloid leukemia].
Kitanaka A
Rinsho Ketsueki; 2016; 57(10):1962-1971. PubMed ID: 27725594
[TBL] [Abstract][Full Text] [Related]
33. Blast and accelerated phase CML: room for improvement.
How J; Venkataraman V; Hobbs GS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):122-128. PubMed ID: 34889372
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
Firwana B; Sonbol MB; Diab M; Raza S; Hasan R; Yousef I; Zarzour A; Garipalli A; Doll D; Murad MH; Al-Kali A
Int J Cancer; 2016 Mar; 138(6):1545-53. PubMed ID: 26455714
[TBL] [Abstract][Full Text] [Related]
35. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Oyekunle A; Klyuchnikov E; Ocheni S; Kröger N; Zander AR; Baccarani M; Bacher U
Acta Haematol; 2011; 126(1):30-9. PubMed ID: 21411987
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
37. Is there a role for allogeneic transplantation in chronic myeloid leukemia?
Benyamini N; Rowe JM
Expert Rev Hematol; 2013 Dec; 6(6):759-65. PubMed ID: 24219552
[TBL] [Abstract][Full Text] [Related]
38. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
[TBL] [Abstract][Full Text] [Related]
39. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
40. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
